About: 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on June 2011

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) наукова стаття, опублікована в червні 2011 (uk) مقالة علمية نشرت في يونيو 2011 (ar) scientific article published on June 2011 (en) artículu científicu espublizáu en xunu de 2011 (ast)
publication date	wds:Q37871699-AC2D6031-2EDE-4CD9-9987-EC1D49D5FA37
publication date	2011-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37871699-09103421-25CC-49F6-A685-AE3153164193
language of work or name	English
author name string	wds:Q37871699-13C1FEA1-B5E6-4800-96D3-BADAC0E2F8F0 wds:Q37871699-44AF11E7-0089-4098-A302-BBA4587FF0A3 wds:Q37871699-46C74B3C-0967-4FE5-A82B-DB7B9F1301FC wds:Q37871699-7C3ACBC1-4045-480F-81FA-27780ADAD4E7 wds:Q37871699-8ACB97B7-8C84-4D05-A0EC-E9E5CF935A29
author name string	Joachim Sieper Martin Rudwaleit Jürgen Braun Rubén Burgos-Vargas Assessment of SpondyloArthritis international Society
rdfs:label	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis (en) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis (nl)
skos:prefLabel	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis (en) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis (nl)
name	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis (en) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis (nl)
author	wds:Q37871699-560FE919-B530-4F38-A1C9-244E555F50AC wds:Q37871699-5672D292-F344-4851-888A-B4F45B198357 wds:Q37871699-AEF27BCA-B47B-4790-A5E4-BDEF02BCB012 wds:Q37871699-C1FE2A7D-1B65-43AB-96F9-B62947F1045A wds:Q37871699-FD514020-372D-4700-93A0-80EE0702FEF1
author	Maxime Dougados Robert Landewé Désirée van der Heijde Walter P Maksymowych Rubén Burgos-Vargas
title	wds:Q37871699-EF80CC9C-DFEE-4E20-A732-CB5DBB659DF9
title	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis (en)
page(s)	wds:Q37871699-CCF7BEBF-8013-42BE-9BD1-D83FA55EBAB0
page(s)	905-908
instance of	wds:Q37871699-C665502A-20D6-4D69-9B08-49C1B838C84C
instance of	scholarly article
main subject	wds:Q37871699-1CDBA63A-F7BF-4CFB-9F61-11C9B95017E3 wds:Q37871699-2A191828-9EDF-464C-983B-A1E3BE722B2E wds:Q37871699-513BA9D1-1316-43FD-B18B-5C7D0A31EE55
main subject	wd:Q18032037 TNF inhibitor Patients
PubMed ID	wds:Q37871699-E52964E7-79A6-4680-8FC9-CE0E188B2C42
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21540200
PubMed ID	21540200
published in	wds:Q37871699-9C2E163C-1036-4A68-B6FD-CB05027CC4BE
published in	Annals of the Rheumatic Diseases
issue	wds:Q37871699-FB81868B-414A-4439-8CE5-B13AC865B6C6
volume	wds:Q37871699-768D80E4-AECE-4568-9BF8-7E456B0EB658
issue	6
volume	70
DOI	wds:Q37871699-E4AC163C-EAB4-4503-AA3E-8CAECA303E00
DOI	http://dx.doi.org/10.1136/ARD.2011.151563
DOI	10.1136/ARD.2011.151563
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37871699
is cites work of	Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis Economic considerations of the treatment of ankylosing spondylitis Developments in therapies for spondyloarthritis Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers New targets in psoriatic arthritis Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Treatment of juvenile idiopathic arthritis: a revolution in care The effect of three years of TNFα blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study Management of arthropathy in inflammatory bowel diseases Biologic therapies for spondyloarthritis: what is new? [Treatment of chronic back pain: current standards]. Secukinumab (AIN457) in the treatment of ankylosing spondylitis Phosphodiesterase 4-targeted treatments for autoimmune diseases Assessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA-B27. Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Delayed diagnosis of ankylosing spondylitis in a Japanese population. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software